The 2-year STEP 5 study discussed here aimed to assess the sustained impact of weekly subcutaneous semaglutide 2.4 mg, in conjunction with behavioral interventions, on body weight and cardiometabolic risks among non-diabetic adults grappling with obesity (BMI 30 kg m2) or overweight (BMI 27 kg m2 with at least one related comorbidity)
While those taking semaglutide (Wegovy) and tirzepatide (Mounjaro) lost double the amount of weight compared with people using older jabs 16kg on average patients put on 9.6kg within a year, meaning they could expect to regain all 16kg again in just over 20 months
For electric cooler users, most modern vehicles provide constant USB or 12-volt power while the engine runs
Our team of experts can help you develop a personalized plan that includes dietary guidance, exercise routines, and ongoing support to help you reach and maintain your desired weight
Ask specifically about your disease stability, which medications might interact, how often they would want to monitor you, and whether they would coordinate with the prescribing physician